Complement-targeted therapy for autoimmune diseases
The success and safety seen in treating complement-mediated hemolysis conditions has sparked the development of targeted therapies for rare autoimmune diseases, with expansion to more common autoimmune conditions. Various classes of drugs, including small molecules, peptides, monoclonal antibodies,...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-12-01
|
| Series: | Medical Review |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/mr-2023-0051 |